Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML

Cyclacel Pharmaceuticals, Inc. CYCC, announced today updated results from an ongoing, multicenter, Phase 1/2 clinical trial examining the safety and efficacy of oral sapacitabine, the Company's lead product candidate, administered sequentially with decitabine. The study enrolled 25 patients aged 70 years or older, 76% of which were aged 75 years or older. Thirty-day mortality from all causes was 4% and 60-day mortality from all causes 12%. The overall response rate was 40%. Median overall survival is 231 days and 44% of patients are still alive. The data were reported during a poster session at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego, California.